The global clinical trial imaging market size is calculated at USD 2.57 billion in 2025 and is forecasted to reach around USD 5.45 billion by 2034, accelerating at a CAGR of 8.78% from 2025 to 2034. The North America clinical trial imaging market size surpassed USD 990 million in 2024 and is expanding at a CAGR of 8.80% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Clinical Trial Imaging Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Clinical Trial Imaging Market, by Service
8.1.1 Clinical Trial Design and Consultation Services
8.1.1.1. Market Revenue and Forecast
8.1.2. Reading and Analytical Services
8.1.2.1. Market Revenue and Forecast
8.1.3. Project and Data Management
8.1.3.1. Market Revenue and Forecast
8.1.4. System and Technology Support Services
8.1.4.1. Market Revenue and Forecast
9.1. Clinical Trial Imaging Market, by Modality
9.1.1. Computed Tomography
9.1.1.1. Market Revenue and Forecast
9.1.2. Ultrasound
9.1.2.1. Market Revenue and Forecast
9.1.3. Magnetic Resonance Imaging
9.1.3.1. Market Revenue and Forecast
9.1.4. Positron Emission Tomography
9.1.4.1. Market Revenue and Forecast
9.1.5. Echocardiography
9.1.5.1. Market Revenue and Forecast
9.1.6. X-Ray
9.1.6.1. Market Revenue and Forecast
9.1.7. Other Modalities
9.1.7.1. Market Revenue and Forecast
10.1. Clinical Trial Imaging Market, by End-Use
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Medical Device Manufacturers
10.1.2.1. Market Revenue and Forecast
10.1.3. Academic and Government Research Institutes
10.1.3.1. Market Revenue and Forecast
10.1.4. Biotechnology Companies
10.1.4.1. Market Revenue and Forecast
10.1.5. Contract Research Organizations
10.1.5.1. Market Revenue and Forecast
10.1.6. Other End-Users
10.1.6.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service
11.1.2. Market Revenue and Forecast, by Modality
11.1.3. Market Revenue and Forecast, by End-Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service
11.1.4.2. Market Revenue and Forecast, by Modality
11.1.4.3. Market Revenue and Forecast, by End-Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service
11.1.5.2. Market Revenue and Forecast, by Modality
11.1.5.3. Market Revenue and Forecast, by End-Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service
11.2.2. Market Revenue and Forecast, by Modality
11.2.3. Market Revenue and Forecast, by End-Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service
11.2.4.2. Market Revenue and Forecast, by Modality
11.2.4.3. Market Revenue and Forecast, by End-Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service
11.2.5.2. Market Revenue and Forecast, by Modality
11.2.5.3. Market Revenue and Forecast, by End-Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service
11.2.6.2. Market Revenue and Forecast, by Modality
11.2.6.3. Market Revenue and Forecast, by End-Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service
11.2.7.2. Market Revenue and Forecast, by Modality
11.2.7.3. Market Revenue and Forecast, by End-Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service
11.3.2. Market Revenue and Forecast, by Modality
11.3.3. Market Revenue and Forecast, by End-Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service
11.3.4.2. Market Revenue and Forecast, by Modality
11.3.4.3. Market Revenue and Forecast, by End-Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service
11.3.5.2. Market Revenue and Forecast, by Modality
11.3.5.3. Market Revenue and Forecast, by End-Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service
11.3.6.2. Market Revenue and Forecast, by Modality
11.3.6.3. Market Revenue and Forecast, by End-Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service
11.3.7.2. Market Revenue and Forecast, by Modality
11.3.7.3. Market Revenue and Forecast, by End-Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service
11.4.2. Market Revenue and Forecast, by Modality
11.4.3. Market Revenue and Forecast, by End-Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service
11.4.4.2. Market Revenue and Forecast, by Modality
11.4.4.3. Market Revenue and Forecast, by End-Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service
11.4.5.2. Market Revenue and Forecast, by Modality
11.4.5.3. Market Revenue and Forecast, by End-Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service
11.4.6.2. Market Revenue and Forecast, by Modality
11.4.6.3. Market Revenue and Forecast, by End-Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service
11.4.7.2. Market Revenue and Forecast, by Modality
11.4.7.3. Market Revenue and Forecast, by End-Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service
11.5.2. Market Revenue and Forecast, by Modality
11.5.3. Market Revenue and Forecast, by End-Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service
11.5.4.2. Market Revenue and Forecast, by Modality
11.5.4.3. Market Revenue and Forecast, by End-Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service
11.5.5.2. Market Revenue and Forecast, by Modality
11.5.5.3. Market Revenue and Forecast, by End-Use
12.1. IXICO plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Intrinsic Imaging
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Resonance Health
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioTelemetry
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Navitas Life Sciences
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. ProScan Imaging
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cardiovascular Imaging Technologies
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Medpace
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Radiant Sage LLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Biomedical Systems Corp
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample